Skip to main content

Table 2 Prevalence of CKD among HIV-infected patients

From: A high likelihood of increase in end-stage renal disease among the Japanese HIV-infected population

 CohortAgeYearCountryReference
Prevalence of any CKD (stages 1–5 or risk zones ≥ yellow)
 14.9%788 HIV46.2 ± 11.8 (all subjects)2010Japan28
 15.4%732 HIV46.7 ± 12.0 (all subjects)2011Japan23
 12.9%1482 HIV44.2 ± 11.4 (all subjects)2013Japan29
 14.1%11447 HIV44.4 ± 11.5 (all subjects)2014Japan24
 15.8%12135 HIV44.5 ± 11.5 (all subjects)2018Japan30
 20.4%21976HIV44.5 ± 11.5 (all subjects)2018Japan30
 15.5%1239 HIV49.2 ± 10.1 (CKD subjects)
45.1 ± 10.6 (non-CKD subjects)
2002US31
 16.8%322 HIV45.2 ± 11.7 (all subjects)2007China32
 23.7%224 HIV46.4 ± 9.4 (CKD subjects)
43.6 ± 8.7 (non-CKD subjects)
2008US33
Prevalence of high-risk CKD (≥ stages 3 or risk zones ≥ orange)
 9.4%788 HIV46.2 ± 11.8 (all subjects)2010Japan28
 9.7%732 HIV46.7 ± 12.0 (all subjects)2011Japan23
 6.7%1482 HIV44.2 ± 11.4 (all subjects)2013Japan29
 6.6%11447 HIV44.4 ± 11.5 (all subjects)2014Japan24
 9.6%12135 HIV44.5 ± 11.5 (all subjects)2018Japan30
 5.3%21976 HIV44.5 ± 11.5 (all subjects)2018Japan30
 3.5%4474 HIV43.4 (38.5–50.8) (all subjects)*2007Europe34
 5.6%322 HIV45.2 ± 11.7 (all subjects)2007China32
 5.9%1239 HIV49.2 ± 10.1 (CKD subjects)
45.1 ± 10.6 (non-CKD subjects)
2002US31
 9.7%224 HIV46.4 ± 9.4 (CKD subjects)
43.6 ± 8.7 (non-CKD subjects)
2008US33
  1. Prevalence without annotation is determined, according to the staging system based on the Kidney Disease Outcomes Quality Initiative (K/DOQI) guidelines
  2. 1Prevalence is determined, according to the CGA classification, using proteinuria with estimated glomerular filtration rate
  3. 2Prevalence is determined, according to the CGA classification, using albuminuria with estimated glomerular filtration rate
  4. *Age is expressed as mean ± standard deviation, except for reference 34, in which median (interquartile range) is employed